36789546|t|Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency.
36789546|a|Multiple sulfatase deficiency (MSD, MIM #272200) results from pathogenic variants in the SUMF1 gene that impair proper function of the formylglycine-generating enzyme (FGE). FGE is essential for the posttranslational activation of cellular sulfatases. MSD patients display reduced or absent sulfatase activities and, as a result, clinical signs of single sulfatase disorders in a unique combination. Up to date therapeutic options for MSD are limited and mostly palliative. We performed a screen of FDA-approved drugs using immortalized MSD patient fibroblasts. Recovery of arylsulfatase A activity served as the primary readout. Subsequent analysis confirmed that treatment of primary MSD fibroblasts with tazarotene and bexarotene, two retinoids, led to a correction of MSD pathophysiology. Upon treatment, sulfatase activities increased in a dose- and time-dependent manner, reduced glycosaminoglycan content decreased and lysosomal position and size normalized. Treatment of MSD patient derived induced pluripotent stem cells (iPSC) differentiated into neuronal progenitor cells (NPC) resulted in a positive treatment response. Tazarotene and bexarotene act to ultimately increase the stability of FGE variants. The results lay the basis for future research on the development of a first therapeutic option for MSD patients.
36789546	26	36	tazarotene	Chemical	MESH:C086827
36789546	41	51	bexarotene	Chemical	MESH:D000077610
36789546	77	106	multiple sulfatase deficiency	Disease	MESH:D052517
36789546	108	137	Multiple sulfatase deficiency	Disease	MESH:D052517
36789546	139	142	MSD	Disease	MESH:D052517
36789546	197	202	SUMF1	Gene	285362
36789546	243	274	formylglycine-generating enzyme	Gene	285362
36789546	276	279	FGE	Gene	285362
36789546	282	285	FGE	Gene	285362
36789546	360	363	MSD	Disease	MESH:D052517
36789546	364	372	patients	Species	9606
36789546	399	408	sulfatase	Gene	347527
36789546	463	482	sulfatase disorders	Disease	MESH:D052517
36789546	543	546	MSD	Disease	MESH:D052517
36789546	645	648	MSD	Disease	MESH:D052517
36789546	649	656	patient	Species	9606
36789546	682	697	arylsulfatase A	Gene	410
36789546	794	797	MSD	Disease	MESH:D052517
36789546	815	825	tazarotene	Chemical	MESH:C086827
36789546	830	840	bexarotene	Chemical	MESH:D000077610
36789546	846	855	retinoids	Chemical	MESH:D012176
36789546	880	883	MSD	Disease	MESH:D052517
36789546	917	926	sulfatase	Gene	347527
36789546	994	1011	glycosaminoglycan	Chemical	MESH:D006025
36789546	1087	1090	MSD	Disease	MESH:D052517
36789546	1091	1098	patient	Species	9606
36789546	1240	1250	Tazarotene	Chemical	MESH:C086827
36789546	1255	1265	bexarotene	Chemical	MESH:D000077610
36789546	1310	1313	FGE	Gene	285362
36789546	1423	1426	MSD	Disease	MESH:D052517
36789546	1427	1435	patients	Species	9606
36789546	Negative_Correlation	MESH:D000077610	285362
36789546	Negative_Correlation	MESH:D012176	MESH:D052517
36789546	Negative_Correlation	MESH:D000077610	MESH:D052517
36789546	Association	MESH:C086827	285362
36789546	Negative_Correlation	MESH:C086827	MESH:D052517
36789546	Association	MESH:D052517	285362
36789546	Negative_Correlation	MESH:C086827	MESH:D006025
36789546	Association	MESH:D052517	347527
36789546	Negative_Correlation	MESH:D000077610	MESH:D006025

